EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY 4.0

Feasibility of two levels of protein intake in patients with colorectal cancer: findings from the Protein Recommendation to Increase Muscle (PRIMe) randomized controlled pilot trial

K L Ford, M B Sawyer, S Ghosh, C F Trottier, I R Disi, J Easaw, K Mulder, S Koski, K N Porter Starr, C W Bales, J Arends, M Siervo und 2 weitere

ESMO Open · 2024-07 · 9 (7) · 103604

DOI: 10.1016/j.esmoop.2024.103604 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift ESMO Open, 2024-07. Verfasst von K L Ford und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Dietary Proteins, Feasibility Studies. Die Arbeit wurde bisher 21-mal zitiert (Crossref) und nennt 64 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: RRD VA.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Low muscle mass (MM) predicts unfavorable outcomes in cancer. Protein intake supports muscle health, but oncologic recommendations are not well characterized. The objectives of this study were to evaluate the feasibility of dietary change to attain 1.0 or 2.0 g/kg/day protein diets, and the preliminary potential to halt MM loss and functional decline in patients starting chemotherapy for stage II-IV colorectal cancer. PATIENTS AND METHODS: Patients were randomized to the diets and provided individualized counseling. Assessments at baseline, 6 weeks, and 12 weeks included weighed 3-day food records, appendicular lean soft tissue index (ALSTI) by dual-energy X-ray absorptiometry to estimate MM, and physical function by the Short Physical Performance Battery (SPPB) test. RESULTS: Fifty patients (mean ± standard deviation: age, 57 ± 11 years; body mass index, 27.3 ± 5.6 kg/m2; and protein intake, 1.1 ± 0.4 g/kg/day) were included at baseline. At week 12, protein intake reached 1.6 g/kg/day in the 2.0 g/kg/day group and 1.2 g/kg/day in the 1.0 g/kg/day group (P = 0.012), resulting in a group difference of 0.4 g/kg/day rather than 1.0 g/kg/day. Over one-half (59%) of patients in the 2.0 g/kg/day group maintained or gained MM compared with 44% of patients in the 1.0 g/kg/day group (P = 0.523). Percent change in ALSTI did not differ between groups [2.0 g/kg/day group (mean ± standard deviation): 0.5% ± 4.6%; 1.0 g/kg/day group: -0.4% ± 6.1%; P = 0.619]. No differences in physical function were observed between groups. However, actual protein intake and SPPB were positively associated (β = 0.37; 95% confidence interval 0.08-0.67; P = 0.014). CONCLUSION: Individualized nutrition counselling positively impacted protein intake. However, 2.0 g/kg/day was not attainable using our approach in this population, and group contamination occurred. Increased protein intake suggested positive effects on MM and physical function, highlighting the potential for nutrition to attenuate MM loss in patients with cancer. Nonetheless, muscle anabolism to any degree is clinically significant and beneficial to patients. Larger trials should explore the statistical significance and clinical relevance of protein interventions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsDietary ProteinsFeasibility StudiesHumansMaleMiddle AgedFemalePilot ProjectsAgedMuscle, SkeletalSarcopenia

Stichwörter der Autor:innen

cancerdietary interventionlow muscle massmuscle lossprotein intake

Substanzen

Dietary Proteins

Autor:innen und Institutionen

  • Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton.
  • Department of Oncology, University of Alberta, Edmonton, Canada.
  • Department of Agricultural, Food & Nutritional Science, University of Alberta, Edmonton; Department of Postgraduate Program of Anaesthesiology, Surgical Sciences and Perioperative Medicine, Faculdade de Medicina da Univ…
  • Durham VA Medical Centre, Durham; Department of Medicine, Duke University, Durham, USA.
  • Department of Medicine I, Medical Center - University of Freiburg, Faculty of Medicine, University of Freiburg, Germany.
  • School of Population Health, Curtin University, Perth, Australia.

Förderung

  • RRD VA

Zitieren

APA

Ford, K. L., Sawyer, M. B., Ghosh, S., Trottier, C. F., Disi, I. R., Easaw, J., Mulder, K., Koski, S., Porter Starr, K. N., Bales, C. W., Arends, J., Siervo, M., Deutz, N., & Prado, C. M. (2024). Feasibility of two levels of protein intake in patients with colorectal cancer: findings from the Protein Recommendation to Increase Muscle (PRIMe) randomized controlled pilot trial. ESMO Open, 9(7), 103604. https://doi.org/10.1016/j.esmoop.2024.103604

Vancouver

Ford KL, Sawyer MB, Ghosh S, Trottier CF, Disi IR, Easaw J, et al. Feasibility of two levels of protein intake in patients with colorectal cancer: findings from the Protein Recommendation to Increase Muscle (PRIMe) randomized controlled pilot trial. ESMO Open. 2024;9(7):103604. doi:10.1016/j.esmoop.2024.103604

BibTeX
@article{Ford2024,
  author = {Ford, K L and Sawyer, M B and Ghosh, S and Trottier, C F and Disi, I R and Easaw, J and Mulder, K and Koski, S and Porter Starr, K N and Bales, C W and Arends, J and Siervo, M and Deutz, N and Prado, C M},
  title = {Feasibility of two levels of protein intake in patients with colorectal cancer: findings from the Protein Recommendation to Increase Muscle (PRIMe) randomized controlled pilot trial},
  journal = {ESMO Open},
  year = {2024},
  volume = {9},
  number = {7},
  pages = {103604},
  doi = {10.1016/j.esmoop.2024.103604}
}
Kostenlos starten →